Compare CETX & DRMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CETX | DRMA |
|---|---|---|
| Founded | 1998 | 2014 |
| Country | United States | United States |
| Employees | 244 | 9 |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.6M | 5.1M |
| IPO Year | N/A | N/A |
| Metric | CETX | DRMA |
|---|---|---|
| Price | $2.58 | $1.32 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $10.00 |
| AVG Volume (30 Days) | ★ 598.0K | 92.8K |
| Earning Date | 05-12-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $20.41 | N/A |
| Revenue Next Year | N/A | $650.00 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.37 | $0.64 |
| 52 Week High | $9.70 | $7.33 |
| Indicator | CETX | DRMA |
|---|---|---|
| Relative Strength Index (RSI) | 45.06 | 50.06 |
| Support Level | $2.41 | $1.13 |
| Resistance Level | $4.07 | $1.40 |
| Average True Range (ATR) | 0.40 | 0.13 |
| MACD | -0.19 | 0.01 |
| Stochastic Oscillator | 11.86 | 34.31 |
Cemtrex Inc is a multi-industry technology company. It has expanded into a range of sectors, including smart technologies, virtual and augmented realities, industrial solutions, and intelligent security systems. The company's operating segment includes the Security segment and the Industrial Services segment. The security segment provides end-to-end security to all industrial, corporate, and governmental security via its owned subsidiary, Vicon. Whereas the AIS part Industrial Service Segment is expertise services for rigging, millwrighting, in-plant maintenance, equipment erection, relocation, and disassembly to diversified customers. It generates maximum revenue from the Industrial Service Segment, and from the USA. It also operates UK, USA, and Other.
Dermata Therapeutics Inc develops and commercializes dermatology products for the treatment of common skin conditions. It focuses on leveraging prior clinical and technical expertise to develop OTC treatments for conditions such as acne, psoriasis, rosacea, and seborrheic dermatitis. The company is currently developing a once-weekly acne treatment system that utilizes an active ingredient from the OTC monograph in combination with the company's Spongilla technology. It intends to apply its Spongilla technology platform across a range of dermatologic and aesthetic skin applications, including intradermal delivery of botulinum toxin. The company's operates in one segment, which is the business of developing, branding, marketing, and commercializing direct to consumer skincare products.